Matches in Wikidata for { <http://www.wikidata.org/entity/Q66398506> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q66398506 description "clinical trial" @default.
- Q66398506 description "ensayu clínicu" @default.
- Q66398506 description "klinisch onderzoek" @default.
- Q66398506 description "клінічне випробування" @default.
- Q66398506 name "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection" @default.
- Q66398506 name "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide" @default.
- Q66398506 type Item @default.
- Q66398506 label "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection" @default.
- Q66398506 label "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide" @default.
- Q66398506 prefLabel "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection" @default.
- Q66398506 prefLabel "Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide" @default.
- Q66398506 P1132 Q66398506-30169943-CDB9-4AE0-A37A-77C1E14DB79D @default.
- Q66398506 P1476 Q66398506-9690564D-B1B8-40DE-9756-0BA76E55C59B @default.
- Q66398506 P17 Q66398506-1C14E48A-0FBA-44CE-A63C-2BCCE8322BCB @default.
- Q66398506 P17 Q66398506-30BE72A9-F938-4BB5-ACBB-C3731FC86C71 @default.
- Q66398506 P17 Q66398506-3652598E-A003-4BF7-A649-C18FAAD6EC84 @default.
- Q66398506 P17 Q66398506-6DAC729F-B0E2-43D0-858A-810613403149 @default.
- Q66398506 P17 Q66398506-86BB6EC3-614B-47D8-94EB-84D406F32BDD @default.
- Q66398506 P17 Q66398506-8F88B5BD-EE1D-43A7-9F42-CF38F13994AB @default.
- Q66398506 P17 Q66398506-9FB95994-E397-4BAA-B158-B9E14303B0AD @default.
- Q66398506 P17 Q66398506-D02399A9-BDFC-432F-BA8C-E3D59DF0B77E @default.
- Q66398506 P17 Q66398506-D1C9930C-3B15-4CA8-A591-0D7FF78AC0A7 @default.
- Q66398506 P17 Q66398506-D86C5ECD-2F3A-4377-BFDF-D41A9C478FCB @default.
- Q66398506 P17 Q66398506-EA15677C-A6BC-490F-954F-25FCF01EF33F @default.
- Q66398506 P1813 Q66398506-B0A79A24-DA97-4C0F-8F92-8E910DD86587 @default.
- Q66398506 P2899 Q66398506-B25C1FC2-4A07-46B3-9DBF-953F5564797B @default.
- Q66398506 P3098 Q66398506-20186DBB-7460-4E34-A964-1554D463E50C @default.
- Q66398506 P31 Q66398506-1248D89D-F02A-4F50-8B6E-01C78BF83AA6 @default.
- Q66398506 P580 Q66398506-5750D0E4-DF1F-4BE3-953F-200C108421EF @default.
- Q66398506 P582 Q66398506-74DC50CB-5C49-4A28-95FB-2616AE9F6090 @default.
- Q66398506 P6099 Q66398506-DB2EF6F7-500F-42A2-B9BA-E2FEA08629FB @default.
- Q66398506 P8363 Q66398506-A2AF18D3-3830-4490-A626-DC15F11BC56B @default.
- Q66398506 P1132 "+5400" @default.
- Q66398506 P1476 "A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection" @default.
- Q66398506 P17 Q142 @default.
- Q66398506 P17 Q145 @default.
- Q66398506 P17 Q16 @default.
- Q66398506 P17 Q183 @default.
- Q66398506 P17 Q27 @default.
- Q66398506 P17 Q29 @default.
- Q66398506 P17 Q30 @default.
- Q66398506 P17 Q35 @default.
- Q66398506 P17 Q38 @default.
- Q66398506 P17 Q40 @default.
- Q66398506 P17 Q55 @default.
- Q66398506 P1813 "DISCOVER" @default.
- Q66398506 P2899 "+18" @default.
- Q66398506 P3098 "NCT02842086" @default.
- Q66398506 P31 Q30612 @default.
- Q66398506 P580 "2016-09-02T00:00:00Z" @default.
- Q66398506 P582 "2019-01-31T00:00:00Z" @default.
- Q66398506 P6099 Q42824827 @default.
- Q66398506 P8363 Q78089383 @default.